Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2002, for OrthoLogic Corp. (Note: The input metadata lists "Capstone Holding Corp.", but the filing text explicitly identifies the registrant as OrthoLogic Corp.). The company develops and markets orthopedic products focused on fracture healing and spinal repair. In July 2001, the company divested its Continuous Passive Motion (CPM) business to refocus on its core segments.
Key Financial Metrics
| Metric | Q2 2002 | Q2 2001 | 6 Months 2002 | 6 Months 2001 |
|---|---|---|---|---|
| Total Net Revenues | $9.7 million | $22.1 million | $19.3 million | $43.8 million |
| Gross Profit | $8.3 million | $18.2 million | $16.6 million | $35.1 million |
| Gross Margin | 85.1% | 82.4% | 85.7% | 80.3% |
| Net Income (Loss) | $1.3 million | ($15.0 million) | $2.7 million | ($14.8 million) |
| EPS (Diluted) | $0.04 | ($0.48) | $0.08 | ($0.47) |
| Cash & Equivalents | $10.5 million | See Liquidity Section | ||
| Short-term Investments | $18.7 million | |||
| Operating Cash Flow (6mo) | $2.2 million (2002) vs $6.2 million (2001) | |||
| Debt | No long-term debt; $4.0 million revolving line of credit (unused). |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 56.1% in Q2 2002 compared to Q2 2001. This decline is primarily due to the divestiture of the CPM business, which contributed $14.0 million in revenue in Q2 2001.
- Core Business Growth: Despite the overall decline, sales of bone growth stimulation products (OL1000 and SpinaLogic) increased 22.2% in Q2 2002 compared to the prior year.
- Profitability Turnaround: The company reported a net profit of $1.3 million in Q2 2002, a significant improvement from a net loss of $15.0 million in Q2 2001. The 2001 loss included a $14.3 million charge related to the CPM divestiture.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses dropped 60.8% year-over-year, largely due to the elimination of variable costs associated with the divested CPM business.
- CPM Receivables Gain: The company recognized a gain of $226,000 in Q2 2002 due to better-than-anticipated collections on retained CPM accounts receivable.
Outlook, Risks, and Management Commentary
- Liquidity: Management anticipates that existing cash, short-term investments, and the $4.0 million line of credit will be sufficient to meet working capital requirements for the next 12 months.
- R&D Pipeline: The company is advancing clinical trials for Chrysalin, a peptide for fracture and spinal repair. In March 2002, the FDA cleared a Phase I/II trial for spinal fusion, triggering a $500,000 milestone payment. A Phase III trial for fresh fracture repair was authorized by the FDA subsequent to June 30, 2002.
- Legal Contingencies:
- CPM Litigation: The company is in litigation with the purchaser of the CPM business regarding a contingent payment of up to $2.5 million and allegations of asset overvaluation. The outcome is currently indeterminable.
- Qui Tam Action: A relator filed a third amended complaint under the False Claims Act regarding pre-acquisition CPM billing practices. The company has filed a motion to dismiss.
- Key Risks: Dependence on third-party payors for reimbursement, reliance on a single supplier for critical microprocessors, and the uncertainty of market acceptance for bone growth stimulators.
Investor Verification Checklist
- Verify the status of the litigation with OrthoRehab regarding the $2.5 million contingent CPM payment and asset valuation claims.
- Monitor the progress and results of the Chrysalin Phase III clinical trials for fresh fracture repair and Phase I/II trials for spinal fusion.
- Assess the sustainability of the 22% growth in core bone growth stimulation products independent of the divested CPM business.
- Review the company's ability to maintain the required financial covenants (tangible net worth, quick ratio) for its $4.0 million line of credit.
- Confirm the renewal status of the sublease for the company's headquarters facility, which expires in December 2002.